![Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs](https://www.unilabs.sk/media/2021/12/1/5/matysova-tab-1.jpg)
Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs
![Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs](https://www.unilabs.sk/media/2021/12/1/5/matysova-tab-2.jpg)
Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs
![IJERPH | Free Full-Text | Safety of Three-Dimensional versus Two-Dimensional Laparoscopic Hysterectomy during the COVID-19 Pandemic IJERPH | Free Full-Text | Safety of Three-Dimensional versus Two-Dimensional Laparoscopic Hysterectomy during the COVID-19 Pandemic](https://www.mdpi.com/ijerph/ijerph-19-14163/article_deploy/html/images/ijerph-19-14163-g001.png)
IJERPH | Free Full-Text | Safety of Three-Dimensional versus Two-Dimensional Laparoscopic Hysterectomy during the COVID-19 Pandemic
![Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs](https://www.unilabs.sk/media/2021/12/1/5/matysova-graf-1-2.jpg)
Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs
MUSC researchers test practical applications of new CT technology developed by Siemens Healthineers | MUSC | Charleston, SC
![Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs](https://www.unilabs.sk/media/2021/12/1/5/matysova-tab-3.jpg)
Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs
![Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs](https://www.unilabs.sk/media/2021/12/1/2/shutterstock-141299494.jpg)
Nádorové markery: Patria do koša, alebo ich vieme efektívne využiť v laboratórnej diagnostike a v klinike? | Unilabs
Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer | PLOS ONE
![Vertically transferred maternal immune cells promote neonatal immunity against early life infections | Nature Communications Vertically transferred maternal immune cells promote neonatal immunity against early life infections | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-24719-z/MediaObjects/41467_2021_24719_Fig1_HTML.png)
Vertically transferred maternal immune cells promote neonatal immunity against early life infections | Nature Communications
![Modelling Chlamydia and HPV co-infection in patient-derived ectocervix organoids reveals distinct cellular reprogramming | Nature Communications Modelling Chlamydia and HPV co-infection in patient-derived ectocervix organoids reveals distinct cellular reprogramming | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-28569-1/MediaObjects/41467_2022_28569_Fig1_HTML.png)
Modelling Chlamydia and HPV co-infection in patient-derived ectocervix organoids reveals distinct cellular reprogramming | Nature Communications
![Cancers | Free Full-Text | Real-World Evidence: How Long Do Our Patients Fast?—Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases Cancers | Free Full-Text | Real-World Evidence: How Long Do Our Patients Fast?—Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases](https://pub.mdpi-res.com/cancers/cancers-15-01311/article_deploy/html/images/cancers-15-01311-g001.png?1676719517)